Savara Inc. (YB4P.F)

4.8400 -0.0400 (-0.82%) As of 09:07AM CEST. Market open.

Savara Inc.

1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Pauls J.D., M.B.A.	Chairman & CEO	900.9k	N/A	1971
Mr. David L. Lowrance CPA	CFO, Chief Administrative Officer & Secretary	619.86k	N/A	1968
Mr. Robert Lutz M.B.A.	Chief Operating Officer	672k	N/A	1970
Ms. Kate McCabe J.D.	Senior VP & General Counsel	N/A	N/A	N/A
Ms. Anne Erickson	Chief Business Officer	N/A	N/A	1972
Brian Maurer	Head of Clinical Operations	N/A	N/A	N/A
Mr. Charles LaPree	Senior Vice President of Global Regulatory Affairs & Quality Assurance	N/A	N/A	N/A
Dr. Peter Clarke Ph.D.	Executive Vice President of Global Technical Operations	N/A	N/A	1960
Dr. Raymond Dennis Pratt FACP, M.D.	Chief Medical Officer	85.34k	N/A	1951
Mr. Scott L. Wilhoit	Executive Vice President of Global Commercial	N/A	N/A	1963

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Corporate governance

Savara Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.